HercepTest is a semi-quantitative immunohistochemical assay for determination of HER2 protein (c-erbB-2 oncoprotein) overexpression in breast cancer tissues routinely processed for histological evaluation and formalin-fixed, paraffin-embedded cancer tissue from patients with metastatic gastric or gastroesophageal junction adenocarcinoma. HercepTest specifically demonstrates overexpression of HER2 protein. HercepTest is indicated as an aid in the assessment of breast and gastric cancer patients for whom Herceptin® (trastuzumab) treatment is being considered and for breast cancer patients for whom PERJETA™ (pertuzumab) or KADCYLA™ (ado-trastuzumab emtansine) treatment is being considered (see Herceptin®, PERJETA™, and KADCYLA™ package inserts).
K5207 has been tailored especially for use on the Dako Autostainer.
HercepTest™, Herceptin®, PERJETA™, and KADCYLA™ are trademarks owned by Genentech, Inc. and/or F. Hoffmann-La Roche Ltd.; HercepTest is subject to an exclusive trademark license to Dako Denmark A/S.